['post-herpetic neuralgia (phn)', 'neuropathic pain', 'painful diabetic peripheral neuropathy (pdpn)']
['asp8477', 'placebo']

        Inclusion Criteria:

          -  PDPN subject must have:

               -  Established diagnosis of diabetes (type I or II) with painful diabetic peripheral
                  neuropathy and glycosylated hemoglobin (HbA1c) ≤ 11% at Screening.

               -  Stable glycemic control (HbA1c ≤ 11%) achieved by a drug regimen for at least 3
                  months prior to Screening.

               -  At least a 1-year history of DPN pain.

               -  Diabetic distal symmetrical polyneuropathy symptoms (including pain) stable for
                  at least the last 3 months prior to Screening based on PI judgment and
                  subject-reported medical history.

          -  PHN subject must have pain present ≥ 6 months after healing of the herpes zoster rash.

        Exclusion Criteria:

          -  Subject has significant pain of an etiology other than PDPN or PHN, or clearly non
             differentiated pain, or plantar fasciitis, heel spurs, tibial neuropathy, Morton's
             neuroma, bunions, metatarsalgia, arthritis in feet, ischemic pain, neurological
             disorders unrelated to diabetic neuropathy, skin condition in area of neuropathy that
             could alter sensation, malignancy, or current orthostatic hypotension, hypo or
             hypertension, syncope or clinically significant ECG, clinical intolerance to
             Non-steroidal anti-inflammatory drugs (NSAIDs) or ASP8477, depression, psychosis or
             psychiatric or neurological illness, BMI of over 35, renal impairment or failure,
             alcohol (ETOH) or drug abuse, GI complaints.

          -  Previous investigational therapy within 28 days or 5 half lives
      